Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | HPGD | P15428 | 6/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | USP2 | O75604 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.44 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17147474 | 0.94 | SLC2A1 (0.45) | ALDH1A1KDM4EHPGDHSD17B10USP2 | |
| SCHEMBL17147463 | 0.91 | ALDH1A1 (0.51) | ALDH1A1KDM4EHPGDHSD17B10USP2 | |
| SCHEMBL17147478 | 0.91 | SLC2A1 (0.45) | ALDH1A1KDM4EHPGDHSD17B10MAPT | |
| SCHEMBL17147510 | 0.90 | ALDH1A1 (0.51) | ALDH1A1KDM4EHPGDHSD17B10USP2 | |
| SCHEMBL17147429 | 0.87 | ALDH1A1 (0.62) | ALDH1A1KDM4EHPGDHSD17B10USP2 | |
| SCHEMBL17147437 | 0.87 | UBE2I (0.46) | ALDH1A1KDM4EHPGDHSD17B10USP2 | |
| SCHEMBL17147492 | 0.86 | ALDH1A1 (0.54) | ALDH1A1KDM4EHPGDHSD17B10USP2 | |
| SCHEMBL17147491 | 0.86 | ALDH1A1 (0.56) | ALDH1A1KDM4EHPGDHSD17B10USP2 | |
| SCHEMBL17147479 | 0.85 | SLC2A1 (0.52) | ALDH1A1KDM4EHPGDHSD17B10USP2 | |
| SCHEMBL17149352 | 0.84 | UBE2I (0.50) | ALDH1A1KDM4EHPGDHSD17B10USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3125884-B1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2019-11-06 | — | — | EP | disclosed |
| US-9394303-B2 | Small molecule inhibitors of MCL-1 and uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394303-B2 | Small molecule inhibitors of MCL-1 and uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150284387-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-08 | — | — | US | disclosed |
| US-20150284387-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284387-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | MCL1, BCL2L1, API5 | ALDH1A1 1518/4885KDM4E 1138/4885HPGD 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.